Xin Lang Cai Jing·2025-09-01 01:53Core Insights - The innovative drug sector is experiencing a significant surge, with companies like Maiwei Biotech hitting a 20% limit up and Baiji Shenzhou rising over 7%, both reaching historical highs [1] - The National Healthcare Security Administration officially announced the preliminary review list of drugs for the 2025 medical insurance and commercial insurance innovative drug directory on August 28, focusing primarily on new drugs [1] - The directories feature "million-dollar" CAR-T products and several "first and only in the world" products, indicating a strong emphasis on groundbreaking therapies [1] Company Performance - Maiwei Biotech achieved a 20% increase, marking a significant milestone in its stock performance [1] - Baiji Shenzhou's stock rose over 7%, also reaching a historical high [1] - Other companies such as Changchun High-tech and Baihua Medicine also hit the limit up, while Zhixiang Jintai, Kangchen Pharmaceutical, Puris, and Wuwei Biotech all saw increases exceeding 10% [1]